Current posture

What matters now

Finch Therapeutics Group is in solicitation on a modified first amended combined plan and disclosure statement, with confirmation scheduled for September 1, 2026; the court's procedures order approved solicitation only, not confirmation. The notice of confirmation hearing and voting procedures Dkt. 307 sets an August 24 voting deadline, an August 25 confirmation-objection deadline, and August 28 deadlines for the voting report and confirmation briefing. Only holders of Class 5 FTG Equity Interests are entitled to vote. The Boston life-sciences company and affiliated debtors commenced these Chapter 11 cases on March 22, 2026 through a voluntary Chapter 11 petition Dkt. 1. After discontinuing development of its lead investigational product, the debtor became a non-operating entity focused on its microbiome intellectual property and patent-enforcement rights. Its first-day declaration says it had exhausted the liquidity needed to await resolution of the Ferring litigation and potential appeals, while carrying an unused Boston lease for which it had stopped paying rent; it sought to reject that lease and pursue a value-maximizing Section 363 sale of its IP and litigation assets. See the CEO's first-day declaration…

Updated Aug 17, 2026